Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Lung Cancer, Health Screening, Early Cancer Detection, Deep Learning
Interventions: CXR-LC; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 77 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infertility (IVF Patients), Oocyte Competence, Sperm DNA Fragmentation, Paternal Age, Sperm Selection
Interventions: Microfluidic sperm separation device, Density grade centrifugation; Device · Other
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 41 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Conditions: ARB, BVMD, Autosomal-Dominant Bestrophinopathy, Best Vitelliform Macular Dystrophy
Interventions: OPGx-BEST1; Genetic
Lead sponsor: Opus Genetics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 5
States / cities: Los Angeles, California • Gainsville, Florida • New York, New York + 2 more

Conditions: Advanced Renal Cell Carcinoma (RCC)
Interventions: Pumitamig, Ipilimumab, Cabozantinib, Casdatifan; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 17
States / cities: Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more

Conditions: Basal Cell Carcinoma of Skin, Squamous Cell Carcinoma (Skin)
Interventions: Two photon microscopy imaging; Device
Lead sponsor: University of Rochester; Other
Eligibility: Not listed
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Victor, New York

Conditions: Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma, Unresectable Meningioma
Interventions: Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Computed Tomography, Biospecimen Collection, Single Photon Emission Computed Tomography; Radiation · Drug · Procedure + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Advanced Solid Tumor
Interventions: ONC-841; Drug
Lead sponsor: OncoC4, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Sacramento, California • Gainesville, Florida • Kissimmee, Florida + 5 more

Conditions: Undifferentiated Connective Tissue Disease
Interventions: Observation; Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Gilteritinib, Magnetic Resonance Imaging, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan

Conditions: Depression in Adolescence, Delayed Sleep Phase
Interventions: TranS-C, Psychoeducation; Behavioral
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 12 Years to 18 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Glioblastoma, IDH-Wildtype
Interventions: Archive Sample Retrieval, Biospecimen Collection, Chest Radiography, Echocardiography Test, EGFR/EGFRvIII Inhibitor WSD0922-FU, Magnetic Resonance Imaging, Temozolomide; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: HPV
Interventions: Gardasil-9, Lidocaine injection, Lorazepam; Biological · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders
Interventions: neck exoskeleton controller; Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cognition
Interventions: Ready-To-Eat Cereal; Other
Lead sponsor: General Mills; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Carcinoma, Hepatocellular, Liver Cell Carcinoma
Interventions: Tislelizumab; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: New Brunswick, New Jersey • The Bronx, New York

Conditions: Renal Impairment, Healthy Volunteers
Interventions: rilzabrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Cytology Specimen Collection Procedure, Diagnostic Laboratory Biomarker Analysis, Medical Chart Review; Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2035
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: Cyclophosphamide, Fludarabine, ACE2016, Pembrolizumab; Drug
Lead sponsor: Acepodia Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: San Diego, California • Denver, Colorado • Nashville, Tennessee + 1 more

Conditions: UTI's
Interventions: FLUSH; Dietary Supplement
Lead sponsor: Bonafide Health; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Harrison, New York

Conditions: Breast Cancer
Interventions: Core Exercise Promotion Program, Affect-based exercise prescription, Effort-based exercise prescription; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Advanced Solid Tumor
Interventions: BG-C137, Anticancer Agents; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • New Haven, Connecticut • Rochester, Minnesota + 3 more

Conditions: Healthy
Interventions: 11C-ARMI; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 105 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gestational Diabetes Mellitus (GDM), Diabetes Type 2, Breastfeeding Continuation, Breastfeeding Support
Interventions: Implementation mapping to develop a multilevel health system strategy for prevention of type 2 diabetes through targeted breastfeeding support for patients with gestational diabetes; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Lower Respiratory Tract Infection, Pneumonia, Asthma, Bronchiolitis, Viral
Interventions: ED Clinical Decision Support (CDS-ED), Transitions Clinical Decision Support (CDS-Tr); Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 6 Months to 17 Years
Enrollment: 2,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Oakland, California • San Francisco, California • Nashville, Tennessee

Search by objective public record fields.

Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT

The EPIC Study: Exploring Paternal Age and the Influence on Blastocyst Culture

Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Machine Learning Analysis of Two-photon Fluorescence Microscopy of Dermatologic Biopsies

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

Undifferentiated Connective Tissue Disease Registry

Gilteritinib for the Treatment of ALK NSCLC

Better Sleep Study

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

HPV Vaccine Reduced Dose

Using Gaze to Enable Head-neck Movements in Patients With Head Drop

Appetite and Cognition Response to a Breakfast Cereal

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function

Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

An Efficacy Study of a Dietary Supplement Drink Mix for Urinary Health Improvement

A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

PET Imaging of Noradrenergic Transmission in the Brain

Pregnancy and Postpartum Breastfeeding Support for Patients With Gestational Diabetes

Reducing Overuse of Antibiotics With Decision Support